Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis

Journal of the American College of Cardiology

Volumn 37, Issue 1, 2001, Pages 286-292

  Przyklenk, Karin ^a,b   Kloner, Robert A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE; ADENOSINE A2 RECEPTOR AGONIST; ANTITHROMBOCYTIC AGENT; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY PERFUSION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; DISEASE EXACERBATION; DRUG EFFECT; DRUG RESPONSE; HEART MUSCLE ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE; ANIMALS; BLOOD FLOW VELOCITY; CORONARY CIRCULATION; CORONARY DISEASE; DISEASE MODELS, ANIMAL; DOGS; PIPERAZINES; PLATELET AGGREGATION;

EID: 0035173674     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)01049-4     Document Type: Article

References (24)

1. Use of sildenafil (Viagra) in patients with cardiovascular disease
2. Erectile dysfunction and sildenafil citrate and the cardiologist
3. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease
4. Overall cardiovascular profile of sildenafil citrate
5. Hemodynamic effects of sildenafil in men with severe coronary artery disease
6. Efficacy and safety of Viagra (sildenafil citrate) in men with cardiovascular disease and erectile dysfunction
7. Adverse cardiovascular events associated with the use of Viagra
8. Effect of sildenafil (Viagra) on coronary blood flow and hemodynamics during exercise
9. Brief antecedent ischemia attenuates platelet-mediated thrombosis in damaged and stenotic canine coronary arteries: Role of adenosine
10. Reperfusion of "hibernating" myocardium contractile function, high energy phosphate content and myocyte injury following 3 hours of sublethal ischemia and 3 hours of reperfusion in the canine heart
11. Hibernating myocardium
12. Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile dysfunction in the anesthetized dog
13. Monophosphoryl lipid A: A novel nitric oxide-mediated therapy to attenuate platelet aggregation?
14. Cyclic flow variations in conscious dog model of coronary artery stenosis and endothelial injury correlate with acute ischemic heart disease syndromes in humans
15. Whole blood platelet aggregometry in humans and animals: A comparative study
16. 2-receptor activation inhibits neutrophil-mediated injury to coronary endothelium
17. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function and the contractile responses of trabeculae carneae and aortic rings in vitro
18. 2 receptor antagonists on platelet aggregation in the rabbit
19. Activation of nitric oxide synthase by ischemia in the perfused heart
20. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries
21. Cyclic nucleotides and phosphodiesterases in platelets
22. Brief myocardial ischemia attenuates platelet in remote, damaged and stenotic carotid arteries
23. Endogenous adenosine inhibits platelet aggregation during myocardial ischemia in dogs
24. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue